Beneficial action potential duration–shortening effects, but deleterious negative inotropism of IKs -activator docosahexaenoyl glycine in long QT syndrome type 2
Europace · 2025
DOI: 10.1093/europace/euaf168 ↗Kurz gefasst
Fachartikel in der Zeitschrift Europace, 2025. Verfasst von Julien Louradour und 16 weiteren Autor:innen. Beteiligte Einrichtung: Translational Cardiology, Institute of Physiology and Department of Cardiology, University of Bern, Bühlplatz 5, Bern 3012, Switzerland. Hauptthemen laut MEDLINE: Long QT Syndrome, Action Potentials, Myocytes, Cardiac, ERG1 Potassium Channel. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bern Center of Precision Medicine Lighthouse, Swedish Research Council, European Research Council.
Abstract (Originalsprache)
Aims
Loss-of-function mutations in KCNQ1 and KCNH2 (α-subunits of the slow delayed IKs and rapid delayed IKr-conducting repolarising K+ channels) lead to long QT syndrome type 1 (LQT1) and 2 (LQT2), respectively. These channelopathies present with longer action potential duration (APD) and prolonged QT interval on electrocardiogram, which can ultimately lead to deadly arrhythmias. Here, we investigated the therapeutic potential of the polyunsaturated fatty acid docosahexaenoyl glycine (DHA-gly) in normalizing APD and QT interval in LQT2 by increasing IKs. Methods and results The effects of DHA-gly on electrical and mechanical parameters were assessed in Xenopus laevis oocytes, wild-type (WT), LQT1 (KCNQ1-Y315S), and LQT2 (KCNH2-G628S) transgenic rabbit models and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). DHA-gly increased IKs in oocytes and WT ventricular cardiomyocytes (VCMs) in a dose-dependent manner. Consequently, DHA-gly shortened APD in vitro and QT interval ex vivo in WT and LQT2 rabbits, but not in LQT1. However, DHA-gly was unable to reduce arrhythmia formation in LQT2. Beneficial APD/QT shortening effects were accompanied by a detrimental decrease in both cellular and ventricular contraction across all genotypes, including LQT1, which could be due to a shortening in Ca2+ transient duration observed in VCMs and hiPSC-CMs.
Conclusion
DHA-gly–induced IKs enhancement shows promising results in shortening APD/QT in LQT2 rabbits, while having no effect on LQT1 (impaired IKs). However, its adverse effect on cardiac contractility, even in LQT1, makes it unsuitable to treat LQTS patients. Our study highlights the importance of considering both electrical and mechanical effects of potential therapeutic compounds prior to clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Cardiology, Institute of Physiology and Department of Cardiology, University of Bern, Bühlplatz 5, Bern 3012, Switzerland.
- Department of Cardiology and Angiology I, University Heart Center Freiburg, Medical Faculty, Hugstetter Straße 55, 79106 Freiburg, Germany.
- Department of Pharmacology and Pharmacotherapy, University of Szeged, Szeged, Hungary.
- Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
- Cardiovascular Research Center, Brown University, Providence, USA.
- Department of Cardiology and Intensive Care, St. Josefskrankenhaus Freiburg, Freiburg, Germany.
ORCID-Profile: Julien Louradour, Tibor Hornyik, Alicia De la Cruz, Nicolò Alerni, Miriam Barbieri, Ruben Lopez, Stefanie Perez-Feliz, Lluís Matas, Saranda Nimani, Lucilla Giammarino, Gideon Koren, Michael Brunner, Sara I Liin, H Peter Larsson, Katja E Odening
Förderung
- Bern Center of Precision Medicine Lighthouse
- Swedish Research Council
- European Research Council
- NHLBI NIH HHS
- NIH ROI
- European Union's Horizon 2020
- European Union’s Horizon 2020
Zitieren
APA
Louradour, J., Hornyik, T., De la Cruz, A., Hiniesto-Iñigo, I., Alerni, N., Barbieri, M., Lopez, R., Perez-Feliz, S., Matas, L., Nimani, S., Giammarino, L., Koren, G., Zehender, M., Brunner, M., Liin, S. I., Larsson, H. P., & Odening, K. E. (2025). Beneficial action potential duration–shortening effects, but deleterious negative inotropism of IKs -activator docosahexaenoyl glycine in long QT syndrome type 2. Europace. https://doi.org/10.1093/europace/euaf168
Vancouver
Louradour J, Hornyik T, De la Cruz A, Hiniesto-Iñigo I, Alerni N, Barbieri M, et al. Beneficial action potential duration–shortening effects, but deleterious negative inotropism of IKs -activator docosahexaenoyl glycine in long QT syndrome type 2. Europace. 2025. doi:10.1093/europace/euaf168
BibTeX
@article{Louradour2025,
author = {Louradour, Julien and Hornyik, Tibor and De la Cruz, Alicia and Hiniesto-Iñigo, Irene and Alerni, Nicolò and Barbieri, Miriam and Lopez, Ruben and Perez-Feliz, Stefanie and Matas, Lluís and Nimani, Saranda and Giammarino, Lucilla and Koren, Gideon and Zehender, Manfred and Brunner, Michael and Liin, Sara I and Larsson, H Peter and Odening, Katja E},
title = {Beneficial action potential duration–shortening effects, but deleterious negative inotropism of IKs -activator docosahexaenoyl glycine in long QT syndrome type 2},
journal = {Europace},
year = {2025},
doi = {10.1093/europace/euaf168}
}
EUVIMED